Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases
Abstract The efficacy and prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) are poor. The third-generation EGFR-tyrosine kinase inhibitor proved to have better intracranial efficacy, which combined with anti-angiogen...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Nature Portfolio
2025-12-01
|
| Цуврал: | npj Precision Oncology |
| Онлайн хандалт: | https://doi.org/10.1038/s41698-025-01191-2 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|